{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T07:50:45Z","timestamp":1759564245425},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2013,5,10]],"date-time":"2013-05-10T00:00:00Z","timestamp":1368144000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Cancer Chemother Pharmacol"],"published-print":{"date-parts":[[2013,7]]},"DOI":"10.1007\/s00280-013-2173-2","type":"journal-article","created":{"date-parts":[[2013,5,9]],"date-time":"2013-05-09T05:29:58Z","timestamp":1368077398000},"page":"101-107","source":"Crossref","is-referenced-by-count":7,"title":["A phase II study of modified dose-dense paclitaxel and every 4-week carboplatin for the treatment of advanced-stage primary epithelial ovarian, fallopian tube, or peritoneal carcinoma"],"prefix":"10.1007","volume":"72","author":[{"given":"Lisa N.","family":"Abaid","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John P.","family":"Micha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mark A.","family":"Rettenmaier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John V.","family":"Brown","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alberto A.","family":"Mendivil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katrina L.","family":"Lopez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bram H.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2013,5,10]]},"reference":[{"key":"2173_CR1","doi-asserted-by":"crossref","first-page":"69","DOI":"10.3322\/caac.20107","volume":"61","author":"A Jemal","year":"2011","unstructured":"Jemal A, Bray F, Center MM et al (2011) Cancer statistics. CA Cancer J Clin 61:69\u201390","journal-title":"CA Cancer J Clin"},{"key":"2173_CR2","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","volume":"21","author":"RF Ozols","year":"2003","unstructured":"Ozols RF, Bundy BN, Greer BE et al (2003) Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study. J Clin Oncol 21:3194\u20133200","journal-title":"J Clin Oncol"},{"key":"2173_CR3","doi-asserted-by":"crossref","first-page":"1682","DOI":"10.1093\/jnci\/djh323","volume":"96","author":"PA Vasey","year":"2004","unstructured":"Vasey PA, Jayson GC, Gordon A et al (2004) Phase III randomized trial of docetaxel-carboplatin versus paclitaxel-carboplatin as first-line chemotherapy for ovarian carcinoma. J Natl Cancer Inst 96:1682\u20131691","journal-title":"J Natl Cancer Inst"},{"key":"2173_CR4","doi-asserted-by":"crossref","first-page":"1642","DOI":"10.1200\/JCO.2007.11.6699","volume":"26","author":"AD Seidman","year":"2008","unstructured":"Seidman AD, Berry D, Cirrincione C et al (2008) Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 26:1642\u20131649","journal-title":"J Clin Oncol"},{"key":"2173_CR5","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.ygyno.2009.04.008","volume":"114","author":"T Safra","year":"2009","unstructured":"Safra T, Menczer J, Bernstein RM et al (2009) Combined weekly carboplatin and paclitaxel as primary treatment of advanced epithelial ovarian carcinoma. Gynecol Oncol 114:215\u2013218","journal-title":"Gynecol Oncol"},{"key":"2173_CR6","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1016\/S0140-6736(09)61157-0","volume":"374","author":"N Katsumata","year":"2009","unstructured":"Katsumata N, Yasuda M, Takahashi F et al (2009) Dose-dense paclitaxel once a week in combination with carboplatin every 3\u00a0weeks for advanced ovarian cancer: a phase 3, open-label, randomised controlled trial. Lancet 374:1331\u20131338","journal-title":"Lancet"},{"key":"2173_CR7","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1016\/j.ygyno.2009.09.031","volume":"116","author":"G Oskay-Ozcelik","year":"2010","unstructured":"Oskay-Ozcelik G, Chekerov R, Sommer H et al (2010) Sequential chemotherapy with carboplatin followed by weekly paclitaxel in advanced ovarian cancer: results of a multicenter phase II study of the northeastern German society of gynecological oncology. Gynecol Oncol 116:317\u2013322","journal-title":"Gynecol Oncol"},{"key":"2173_CR8","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1200\/JCO.2004.08.065","volume":"22","author":"H Burris III","year":"2004","unstructured":"Burris H III, Yardley D, Jones S, Thompson D, Greco FA, White M, Hainsworth J et al (2004) Phase II trial of trastuzumab followed by weekly paclitaxel\/carboplatin as first-line treatment for patients with metastatic breast cancer. J Clin Oncol 22:1621\u20131629","journal-title":"J Clin Oncol"},{"key":"2173_CR9","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1046\/j.1525-1438.2001.011004295.x","volume":"11","author":"CH Wu","year":"2001","unstructured":"Wu CH, Yang CH, Lee JN et al (2001) Weekly and monthly regimens of paclitaxel and carboplatin in the management of advanced ovarian cancer. A preliminary report on side effects. Int J Gynecol Cancer 11:295\u2013299","journal-title":"Int J Gynecol Cancer"},{"key":"2173_CR10","first-page":"2099","volume":"85","author":"K Shen","year":"2005","unstructured":"Shen K, Li MD, Feng YJ et al (2005) A multicenter randomized clinical trial of weekly paclitaxel and carboplatin versus three weeks paclitaxel and carboplatin as first line chemotherapy in epithelial ovarian cancer. Zhonghua Yi Xue Za Zhi 85:2099\u20132103","journal-title":"Zhonghua Yi Xue Za Zhi"},{"key":"2173_CR11","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1016\/j.ygyno.2005.10.036","volume":"101","author":"M Markman","year":"2006","unstructured":"Markman M, Blessing J, Rubin SC et al (2006) Phase II trial of weekly paclitaxel (80\u00a0mg\/m2) in platinum and paclitaxel-resistant ovarian and primary peritoneal cancers: a Gynecologic Oncology Group study. Gynecol Oncol 101:436\u2013440","journal-title":"Gynecol Oncol"},{"key":"2173_CR12","doi-asserted-by":"crossref","first-page":"1303","DOI":"10.1016\/S0140-6736(09)61305-2","volume":"374","author":"MA Bookman","year":"2009","unstructured":"Bookman MA (2009) Dose-dense chemotherapy in advanced ovarian cancer. Lancet 374:1303\u20131305","journal-title":"Lancet"},{"key":"2173_CR13","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1111\/IGC.0b013e3181e94331","volume":"20","author":"JV Brown III","year":"2010","unstructured":"Brown JV III, Micha JP, Rettenmaier MA et al (2010) A pilot study evaluating a novel regimen comprised of carboplatin, paclitaxel, and bevacizumab for advanced-stage ovarian carcinoma. Int J Gynecol Cancer 20:1132\u20131136","journal-title":"Int J Gynecol Cancer"},{"key":"2173_CR14","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1016\/j.ygyno.2007.10.022","volume":"108","author":"EL Eisenhauer","year":"2008","unstructured":"Eisenhauer EL, Abu-Rustum NR, Sonoda Y et al (2008) The effect of maximal surgical cytoreduction on sensitivity to platinum-taxane chemotherapy and subsequent survival in patients with advanced ovarian cancer. Gynecol Oncol 108:276\u2013281","journal-title":"Gynecol Oncol"},{"key":"2173_CR15","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1200\/JCO.2008.19.1684","volume":"27","author":"MA Bookman","year":"2009","unstructured":"Bookman MA, Brady MF, McGuire WP et al (2009) Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup. J Clin Oncol 27:1419\u20131425","journal-title":"J Clin Oncol"},{"key":"2173_CR16","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1006\/gyno.1997.4916","volume":"68","author":"JV Brown","year":"1998","unstructured":"Brown JV, Rettenmaier MA, Dillman RA et al (1998) Three-hour paclitaxel infusion and carboplatin is an effective outpatient treatment for stage III epithelial ovarian cancer. Gynecol Oncol 68:166\u2013168","journal-title":"Gynecol Oncol"},{"key":"2173_CR17","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1002\/1097-0142(19940815)74:4<1377::AID-CNCR2820740431>3.0.CO;2-U","volume":"74","author":"JD Hainsworth","year":"1994","unstructured":"Hainsworth JD, Greco F (1994) Paclitaxel administered by 1-hour infusion. Cancer 74:1377\u20131382","journal-title":"Cancer"},{"key":"2173_CR18","doi-asserted-by":"crossref","first-page":"1748","DOI":"10.1200\/JCO.1989.7.11.1748","volume":"7","author":"AH Calvert","year":"1989","unstructured":"Calvert AH, Newell DR, Gunbrell LA et al (1989) Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 7:1748\u20131756","journal-title":"J Clin Oncol"},{"key":"2173_CR19","doi-asserted-by":"crossref","first-page":"605","DOI":"10.7326\/0003-4819-79-4-604","volume":"79","author":"RW Jelliffe","year":"1973","unstructured":"Jelliffe RW (1973) Creatinine clearance: bedside estimate. Ann Intern Med 79:605","journal-title":"Ann Intern Med"},{"key":"2173_CR20","unstructured":"NIH (2010) Common terminology criteria for adverse events (version 4.03). Washington: National Institute of Health"},{"key":"2173_CR21","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1111\/j.1365-2354.2009.01121.x","volume":"19","author":"A L\u00f3pez-Pousa","year":"2010","unstructured":"L\u00f3pez-Pousa A, Rif\u00e0 J, Casas de Tejerina A et al (2010) Risk assessment model for first-cycle chemotherapy-induced neutropenia in patients with solid tumours. Eur J Cancer Care 19:648\u2013655","journal-title":"Eur J Cancer Care"},{"key":"2173_CR22","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2003.07.013","volume":"21","author":"M Markman","year":"2003","unstructured":"Markman M, Liu PY, Wilczynski S et al (2003) Phase III randomized trial of 12 versus 3\u00a0months of maintenance paclitaxel in patients with advanced ovarian cancer after complete response to platinum and paclitaxel-based chemotherapy: a southwest oncology group and gynecologic oncology group trial. J Clin Oncol 21:2460\u20132465","journal-title":"J Clin Oncol"},{"key":"2173_CR23","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1159\/000100987","volume":"71","author":"JP Micha","year":"2006","unstructured":"Micha JP, Goldstein BH, Graham C et al (2006) Improved survival with single-agent paclitaxel consolidation\/maintenance therapy in advanced ovarian carcinoma. Oncology 71:49\u201353","journal-title":"Oncology"},{"key":"2173_CR24","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","volume":"92","author":"P Therasse","year":"2000","unstructured":"Therasse P, Arbuck SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer. National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205\u2013216","journal-title":"J Natl Cancer Inst"},{"key":"2173_CR25","doi-asserted-by":"crossref","first-page":"4054","DOI":"10.1200\/JCO.2001.19.20.4054","volume":"19","author":"GJ Rustin","year":"2001","unstructured":"Rustin GJ, Marples M, Nelstrop AE (2001) Use of CA-125 to define progression of ovarian cancer in patients with persistently elevated levels. J Clin Oncol 19:4054\u20134057","journal-title":"J Clin Oncol"},{"key":"2173_CR26","first-page":"81","volume":"56","author":"GH Eltabbakh","year":"2004","unstructured":"Eltabbakh GH (2004) Recent advances in the management of women with ovarian cancer. Minerva Ginecol 56:81\u201389","journal-title":"Minerva Ginecol"},{"key":"2173_CR27","doi-asserted-by":"crossref","first-page":"149s","DOI":"10.1200\/JCO.2003.02.553","volume":"21","author":"MA Bookman","year":"2003","unstructured":"Bookman MA (2003) Developmental chemotherapy and management of recurrent ovarian cancer. J Clin Oncol 21:149s\u2013167s","journal-title":"J Clin Oncol"},{"key":"2173_CR28","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1007\/s00280-007-0466-z","volume":"61","author":"J Sehouli","year":"2008","unstructured":"Sehouli J, Stengel D, Mustea A et al (2008) Weekly paclitaxel and carboplatin (PC-W) for patients with primary advanced ovarian cancer: results of a multicenter phase-II study of the NOGGO. Cancer Chemother Pharmacol 61:243\u2013250","journal-title":"Cancer Chemother Pharmacol"},{"key":"2173_CR29","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/j.ygyno.2007.01.039","volume":"105","author":"DK Armstrong","year":"2007","unstructured":"Armstrong DK, Bookman MA, McGuire W (2007) A phase I study of paclitaxel, topotecan, cisplatin and Filgrastim in patients with newly diagnosed advanced ovarian epithelial malignancies: a Gynecologic Oncology Group study. Gynecol Oncol 105:667\u2013671","journal-title":"Gynecol Oncol"},{"key":"2173_CR30","doi-asserted-by":"crossref","first-page":"3615","DOI":"10.1200\/JCO.2006.09.4540","volume":"25","author":"PY Liu","year":"2007","unstructured":"Liu PY, Alberts DS, Monk BJ et al (2007) An early signal of CA-125 progression for ovarian cancer patients receiving maintenance treatment after complete clinical response to primary therapy. J Clin Oncol 25:3615\u20133620","journal-title":"J Clin Oncol"},{"key":"2173_CR31","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1111\/IGC.0b013e31819c55c9","volume":"19","author":"JP Micha","year":"2009","unstructured":"Micha JP, Goldstein BH, Rettenmaier MA et al (2009) Clinical utility of CA-125 for maintenance therapy in the treatment of advanced stage ovarian carcinoma. Int J Gynecol Cancer 19:239\u2013241","journal-title":"Int J Gynecol Cancer"},{"key":"2173_CR32","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1159\/000320579","volume":"78","author":"LN Abaid","year":"2010","unstructured":"Abaid LN, Goldstein BH, Micha JP et al (2010) Improved overall survival with 12 cycles of single-agent paclitaxel maintenance therapy following a complete response to induction chemotherapy in advanced ovarian carcinoma. Oncology 78:389\u2013393","journal-title":"Oncology"},{"key":"2173_CR33","first-page":"CD007565","volume":"10","author":"A Elattar","year":"2011","unstructured":"Elattar A, Bryant A, Winter-Roach BA et al (2011) Optimal primary surgical treatment for advanced epithelial ovarian cancer. Cochrane Database Syst Rev 10:CD007565","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Cancer Chemotherapy and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2173-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00280-013-2173-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00280-013-2173-2","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,5,28]],"date-time":"2019-05-28T10:11:29Z","timestamp":1559038289000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00280-013-2173-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,5,10]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2013,7]]}},"alternative-id":["2173"],"URL":"https:\/\/doi.org\/10.1007\/s00280-013-2173-2","relation":{},"ISSN":["0344-5704","1432-0843"],"issn-type":[{"value":"0344-5704","type":"print"},{"value":"1432-0843","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,5,10]]}}}